:format(webp)/cdn.mskdoctors.com/storage/2026/6/2UJUhBZFPCoLOjvJ34pNRIWciXkH2gVf.jpg)
ChondroFiller availability across EuropeChondroFiller is an injectable collagen scaffold that gels in place and recruits the patient's own cells to repair cartilage defects. CE-marked Class III in Europe, it is available in UK private clinics under the brand Liquid Cartilage™, from £3,000 per injection.ChondroFiller is an injectable collagen scaffold that gels in place and recruits the patient's own cells to repair cartilage defects. CE-marked Class III in Europe, it is available in UK private clinics under the brand Liquid Cartilage™, from £3,000 per injection.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/lyQMcAgzZMbtibP8sOhQYJny9z9n8wrf.jpg)
Finding a ChondroFiller specialist in the UKChondroFiller injection for focal cartilage defects requires real-time ultrasound guidance during placement. Most UK clinics lack this capability, so trained specialists concentrate in London.ChondroFiller injection for focal cartilage defects requires real-time ultrasound guidance during placement. Most UK clinics lack this capability, so trained specialists concentrate in London.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/57s18HJqAXR5l5fNKN3AOCVygSdgfLOY.jpg)
ChondroFiller durability vs Arthrosamid and hyaluronic acidChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Lj6L1IaL5TBE3CuCl6wA8ci1T5bHoA72.jpg)
ChondroFiller success rates in practiceChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
